EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma

Aurelia Chacon, Xavier Leleu, Arthur Bobin

Cancers · 23.03.2023 · 15 (7) · 1929

DOI: 10.3390/cancers15071929 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.03.2023. Verfasst von Aurelia Chacon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hematological Department, University of Poitiers Hospital, 86000 Poitiers, France. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of multiple myeloma (MM) has greatly evolved these past few years. Recent advances in therapeutics have largely benefited elderly patients now renamed “non-transplant-eligible” (NTE) patients. Since the 1960s, and for several decades, chemotherapy was the only treatment for MM. Then, the field was marked by the emergence of targeted therapies in the 2000s, such as immunomodulating agents (thalidomide, lenalidomide, and pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), which were the first steps towards an increase in survival. Thereafter, the apparition of monoclonal antibodies (mAbs) was considered a milestone in the treatment of MM for both transplant-eligible and NTE patients. Anti-CD38 mAbs can be safely administered to older patients with an impressive efficacy leading to a never-achieved-before survival rate with the triple association of anti-CD38 mAbs, lenalidomide, and dexamethasone. However, progress is still expected with the introduction in the armamentarium for NTE patients of the most recent innovative immunotherapy-based treatments newly introduced in MM, e.g., CAR-T cells and bispecific antibodies. These “improved versions” of immune-based treatments will probably also benefit NTE patients, although further studies will be needed to better understand their role in this population.

Schlagwörter

Stichwörter der Autor:innen

CAR-Tsbispecific antibodieselderlyimmunotherapymonoclonal antibodiesmultiple myelomanon-transplant-eligible

Autor:innen und Institutionen

  • Hematological Department, University of Poitiers Hospital, 86000 Poitiers, France.
  • Service d'Hématologie et Thérapie Cellulaire, PRC, Université de Poitiers, Inserm IC 1402 and U 1313, CHU, 2 Rue de la Milétrie, Cedex, 86021 Poitiers, France.

Zitieren

APA

Chacon, A., Leleu, X., & Bobin, A. (2023). 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma. Cancers, 15(7), 1929. https://doi.org/10.3390/cancers15071929

Vancouver

Chacon A, Leleu X, Bobin A. 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma. Cancers. 2023;15(7):1929. doi:10.3390/cancers15071929

BibTeX
@article{Chacon2023,
  author = {Chacon, Aurelia and Leleu, Xavier and Bobin, Arthur},
  title = {30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {7},
  pages = {1929},
  doi = {10.3390/cancers15071929}
}
Kostenlos starten →